BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32367407)

  • 1. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis.
    Deodhar A; Chakravarty SD; Cameron C; Peterson S; Hensman R; Fogarty S; Spin P; Kafka S; Nair S; Gensler LS
    Clin Rheumatol; 2020 Aug; 39(8):2307-2315. PubMed ID: 32107666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
    Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.
    van Bentum RE; Heslinga SC; Nurmohamed MT; Gerards AH; Griep EN; Koehorst CBJM; Kok MR; Schilder AM; Verhoef M; van der Horst-Bruinsma IE
    J Rheumatol; 2019 Feb; 46(2):153-159. PubMed ID: 30385705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
    Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
    Deodhar AA; Shiff NJ; Gong C; Hsia EC; Lo KH; Kim L; Xu S; Reveille JD
    J Clin Rheumatol; 2022 Aug; 28(5):270-277. PubMed ID: 35653615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee E; Lee SK; Park YB; Shin K
    BioDrugs; 2020 Aug; 34(4):529-539. PubMed ID: 32696266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
    Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
    J Rheumatol; 2016 Sep; 43(9):1704-12. PubMed ID: 27422890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Meta-Analysis in Ankylosing Spondylitis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
    Wu Y; Feng X; Li J; Wang X; Yang C; Zhao L
    Clin Pharmacol Ther; 2019 May; 105(5):1244-1255. PubMed ID: 30450610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
    Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
    Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):101-7. PubMed ID: 23696633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.